Introduction to Orchard Therapeutics

Sue Rogers, Orchard Therapeutics

An introduction to Orchard Therapeutics. Early in 2018 Orchard acquired the Milano (Italian) gene therapy IP (intellectual property) from GSK (GlaxoSmithKline). This is their first public presentation to the MLD community. OTL-200 is the MLD project name.
20 min, ©2018

if you have trouble viewing any of these videos. Please note Windows, Mac, or phone model ... and what browser name & version you are using.